RUNX2 expression has been correlated with tumor size, tumor stage, lymph node metastasis, and shorter postoperative survival time, suggesting that it might become a novel prognostic marker in NSCLC [56]. This evidence concerns the gene RUNX2 and metastatic malignant neoplasm in the lymph nodes.